Cargando…
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
BACKGROUND: Retrospective studies suggest a survival benefit when platinum-based chemotherapy is administered to patients with pancreatic cancer harbouring a germline mutation in BRCA1, BRCA2 or PALB2 (mut-positive PDAC). However, the objective response rate (ORR) and real-world progression free sur...
Autores principales: | Wattenberg, Max M., Asch, Daniella, Yu, Shun, O’Dwyer, Peter J., Domchek, Susan M., Nathanson, Katherine L., Rosen, Mark A., Beatty, Gregory L., Siegelman, Evan S., Reiss, Kim A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000723/ https://www.ncbi.nlm.nih.gov/pubmed/31787751 http://dx.doi.org/10.1038/s41416-019-0582-7 |
Ejemplares similares
-
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
por: Seeber, Andreas, et al.
Publicado: (2020) -
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017) -
PALB2 (partner and localizer of BRCA2)
por: Hanenberg, Helmut, et al.
Publicado: (2018) -
Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
por: Takeuchi, Shoko, et al.
Publicado: (2018) -
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years
por: Petridis, Christos, et al.
Publicado: (2019)